JPS63287723A - ドーパミン受容体アゴニスト - Google Patents
ドーパミン受容体アゴニストInfo
- Publication number
- JPS63287723A JPS63287723A JP63109280A JP10928088A JPS63287723A JP S63287723 A JPS63287723 A JP S63287723A JP 63109280 A JP63109280 A JP 63109280A JP 10928088 A JP10928088 A JP 10928088A JP S63287723 A JPS63287723 A JP S63287723A
- Authority
- JP
- Japan
- Prior art keywords
- smoking
- day
- dopamine receptor
- treatment
- bromocriptine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title claims description 24
- 229940098778 Dopamine receptor agonist Drugs 0.000 title claims description 7
- 206010057852 Nicotine dependence Diseases 0.000 claims description 15
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 description 39
- 235000019504 cigarettes Nutrition 0.000 description 18
- 241000208125 Nicotiana Species 0.000 description 15
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 15
- 229960002802 bromocriptine Drugs 0.000 description 14
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 13
- 239000000779 smoke Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229940065155 bromocriptine 2.5 mg Drugs 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- 206010043903 Tobacco abuse Diseases 0.000 description 3
- 235000019788 craving Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 229960003587 lisuride Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 229960004851 pergolide Drugs 0.000 description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- -1 compound bromocriptine mesylate Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4775387A | 1987-05-07 | 1987-05-07 | |
| US047753 | 1987-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63287723A true JPS63287723A (ja) | 1988-11-24 |
Family
ID=21950776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63109280A Pending JPS63287723A (ja) | 1987-05-07 | 1988-05-06 | ドーパミン受容体アゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS63287723A (enExample) |
| KR (1) | KR880013556A (enExample) |
| AU (1) | AU622614B2 (enExample) |
| CH (1) | CH675834A5 (enExample) |
| DE (1) | DE3814521A1 (enExample) |
| DK (1) | DK245388A (enExample) |
| FR (1) | FR2614789B1 (enExample) |
| GB (1) | GB2204240B (enExample) |
| IT (1) | IT1219564B (enExample) |
| NL (1) | NL8801171A (enExample) |
| PH (1) | PH25495A (enExample) |
| SE (1) | SE8801708L (enExample) |
| ZA (1) | ZA883237B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797405A (en) * | 1987-10-26 | 1989-01-10 | Eli Lilly And Company | Stabilized pergolide compositions |
| DE19626621A1 (de) * | 1996-07-02 | 1998-01-08 | Hexal Ag | Pflaster zur transdermalen Anwendung von Pergolid |
| US6623752B1 (en) | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR861128B (en) * | 1985-05-06 | 1986-08-26 | Sandoz Ag | New use of dopamine agonists |
| DE3722383A1 (de) * | 1986-07-14 | 1988-01-28 | Sandoz Ag | Neue verwendung von bromocriptin |
-
1988
- 1988-04-29 DE DE3814521A patent/DE3814521A1/de not_active Withdrawn
- 1988-05-02 FR FR888805957A patent/FR2614789B1/fr not_active Expired - Lifetime
- 1988-05-03 IT IT47906/88A patent/IT1219564B/it active
- 1988-05-04 NL NL8801171A patent/NL8801171A/nl not_active Application Discontinuation
- 1988-05-04 CH CH1664/88A patent/CH675834A5/de not_active IP Right Cessation
- 1988-05-04 GB GB8810509A patent/GB2204240B/en not_active Expired - Lifetime
- 1988-05-05 SE SE8801708A patent/SE8801708L/ not_active Application Discontinuation
- 1988-05-05 ZA ZA883237A patent/ZA883237B/xx unknown
- 1988-05-05 AU AU15605/88A patent/AU622614B2/en not_active Expired - Fee Related
- 1988-05-05 DK DK245388A patent/DK245388A/da not_active Application Discontinuation
- 1988-05-06 PH PH36895A patent/PH25495A/en unknown
- 1988-05-06 JP JP63109280A patent/JPS63287723A/ja active Pending
- 1988-05-06 KR KR1019880005250A patent/KR880013556A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DK245388D0 (da) | 1988-05-05 |
| SE8801708L (sv) | 1988-11-08 |
| KR880013556A (ko) | 1988-12-21 |
| FR2614789B1 (fr) | 1991-10-18 |
| AU622614B2 (en) | 1992-04-16 |
| DK245388A (da) | 1988-11-08 |
| GB2204240A (en) | 1988-11-09 |
| AU1560588A (en) | 1988-11-10 |
| IT1219564B (it) | 1990-05-18 |
| PH25495A (en) | 1991-07-24 |
| SE8801708D0 (sv) | 1988-05-05 |
| CH675834A5 (enExample) | 1990-11-15 |
| IT8847906A0 (it) | 1988-05-03 |
| NL8801171A (nl) | 1988-12-01 |
| GB2204240B (en) | 1991-04-24 |
| GB8810509D0 (en) | 1988-06-08 |
| FR2614789A1 (fr) | 1988-11-10 |
| ZA883237B (en) | 1990-01-31 |
| DE3814521A1 (de) | 1988-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rose et al. | Nicotine–mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. | |
| US4935429A (en) | Method of treating psychostimulant addiction | |
| Malhotra et al. | Nicotine and periodontal tissues | |
| US5783207A (en) | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine | |
| US20020019421A1 (en) | Compositions and therapy for substance addiction | |
| US4800204A (en) | Method of controlling tobacco use | |
| KR101767273B1 (ko) | 중독의 예방 및 치료용 조성물 및 방법 | |
| US6166032A (en) | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use | |
| US5480651A (en) | Composition and method for treating nicotine craving in smoking cessation | |
| AU782403B2 (en) | Method for reducing or eliminating smoking | |
| PL196334B1 (pl) | Zastosowanie agonistów receptorów GABA B i ich farmaceutycznie dopuszczalnych pochodnych w terapii abstynencji nikotynowej u uzależnionych od nikotyny pacjentów | |
| Jarvis | Theoretical Background and Clinical | |
| WO1990000896A1 (en) | USE OF BENZO(g)QUINOLINES IN TREATMENT OF NICOTINE ADDICTION | |
| US5414005A (en) | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation | |
| AU622614B2 (en) | Improvements in or relating to organic compounds | |
| Suchanek Hudmon et al. | Current approaches to pharmacotherapy for smoking cessation | |
| EP0204954A2 (en) | Use of dopamine agonists for the manufacture of a medicament for the treatment of psychostimulant addiction | |
| US20020168403A1 (en) | Compositions and therapy for substance addiction | |
| WO1995011679A1 (en) | Use of lobeline for the treatment of nicotine withdrawal | |
| AU2001284704B2 (en) | Method for reducing or eliminating smoking | |
| JPH07505367A (ja) | 喫煙停止におけるニコチン渇望の処置のための副交感神経作用剤とムスカリン性拮抗剤との配合 | |
| JPH07196494A (ja) | 強迫性障害および消費性障害を抑制するための医薬組成物 | |
| Ostrowski et al. | Pharmacologic management of patients using smoking cessation aids | |
| JP2000515548A (ja) | ニコチン禁断症状を処置する方法 | |
| Chu | Nicotine replacement therapy for tobacco use cessation: reference table |